{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:21:14Z","timestamp":1793118074368,"version":"4.5.0"},"reference-count":53,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MIRNA"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a\nmajor contributor to global morbidity and mortality. As diagnostic tools for MASLD remain limited,\nmicroRNAs (miRs) have garnered attention as promising biomarkers due to their roles in regulating\nmetabolic pathways and reflecting disease states.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This systematic review of clinical studies explores the association between miRNAs and\nthe spectrum of MASLD-related pathologies, including steatosis, fibrosis, and Hepatocellular Carcinoma\n(HCC). A comprehensive literature search was conducted using PRISMA guidelines, resulting\nin 44 peer-reviewed studies being included. The review identifies several key miRs, such as\nmiR-122, miR-34a, and miR-193-5p, which are linked to lipid metabolism, insulin resistance, and\nMASLD severity. Results: Additionally, miR-214 and miR-193-5p are highlighted as potential biomarkers\nfor fibrosis, while miR-21 and miR-34a are implicated in the progression of HCC. These\nmiRs were found in various tissues, including serum, liver, visceral adipose tissue, and ascitic fluid,\ndemonstrating their utility as diagnostic and prognostic tools across the MASLD spectrum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>While miR panels are being developed for clinical assessment, further research is required\nto confirm their roles in diagnosis and treatment, as well as their integration into routine\nclinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0122115366359521250122115511","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T05:15:56Z","timestamp":1739337356000},"page":"214-225","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["MicroRNAs in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review of Clinical Studies"],"prefix":"10.2174","volume":"14","author":[{"given":"Eleni","family":"Antoniou","sequence":"first","affiliation":[{"name":"Department of Cardiology, General Hospital of Corinthos, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Oikonomou","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, &#34;Sotiria&#34; Chest DiseaseHospital, University of Athens Medical School, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Theofilis","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, &#34;Ippokrateio&#34; General Hospital,University of Athens Medical School, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Lambadiari","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, Attikon University Hospital, University of Athens Medical School, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kassi","sequence":"additional","affiliation":[{"name":"1st Department of Propaedeutic and Internal Medicine, Division of Diabetes, Laiko University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Chasikidis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, General Hospital of Corinthos, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Zisimos","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, &#34;Sotiria&#34; Chest DiseaseHospital, University of Athens Medical School, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Andreou","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, &#34;Sotiria&#34; Chest DiseaseHospital, University of Athens Medical School, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Kalogera","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, &#34;Sotiria&#34; Chest DiseaseHospital, University of Athens Medical School, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ourania","family":"Katsarou","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, &#34;Sotiria&#34; Chest DiseaseHospital, University of Athens Medical School, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Foti","sequence":"additional","affiliation":[{"name":"Department of Radiology and Medical Imaging, Athens General Hospital &#34;G. Gennimatas,&#34; Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kleopa","sequence":"additional","affiliation":[{"name":"Department of Radiology and Medical Imaging, Athens General Hospital &#34;G. Gennimatas,&#34; Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasia","family":"Striki","sequence":"additional","affiliation":[{"name":"Department ofGastroenterology, General Hospital of Athens &#34;G. Gennimatas,&#34; Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Siasos","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, &#34;Sotiria&#34; Chest DiseaseHospital, University of Athens Medical School, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"78555","DOI":"10.1007\/s11356-022-21090-4","volume":"29","author":"Nguyen H.D.","year":"2022","unstructured":"Nguyen H.D.; Kim M.S.; Effects of chemical mixtures on liver function biomarkers in the Korean adult population: Thresholds and molecular mechanisms for non-alcoholic fatty liver disease involved. Environ Sci Pollut Res Int  2022,29(52),78555-78587","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1126\/science.1113329","volume":"309","author":"Jopling C.L.","year":"2005","unstructured":"Jopling C.L.; Yi M.; Lancaster A.M.; Lemon S.M.; Sarnow P.; Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science  2005,309(5740),1577-1581","journal-title":"Science"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.2147\/DMSO.S231321","volume":"12","author":"Hendy O.M.","year":"2019","unstructured":"Hendy O.M.; Rabie H.; El Fouly A.; The circulating micro-RNAs (\u2212122, \u221234a and \u221299a) as predictive biomarkers for non-alcoholic fatty liver diseases. Diabetes Metab Syndr Obes  2019,12,2715-2723","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/hep4.1501","volume":"4","author":"Ezaz G.","year":"2020","unstructured":"Ezaz G.; Trivedi H.D.; Connelly M.A.; Differential associations of circulating micrornas with pathogenic factors in NAFLD. Hepatol Commun  2020,4(5),670-680","journal-title":"Hepatol Commun"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"111738","DOI":"10.1016\/j.yexcr.2019.111738","volume":"387","author":"Zhao Z.","year":"2020","unstructured":"Zhao Z.; Zhong L.; Li P.; Cholesterol impairs hepatocyte lysosomal function causing M1 polarization of macrophages via exosomal miR-122-5p. Exp Cell Res  2020,387(1),111738","journal-title":"Exp Cell Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/biomedicines10010195","volume":"10","author":"Newman L.A.","year":"2022","unstructured":"Newman L.A.; Useckaite Z.; Johnson J.; Sorich M.J.; Hopkins A.M.; Rowland A.; Selective isolation of liver-derived extracellular vesicles redefines performance of miRNA biomarkers for non-alcoholic fatty liver disease. Biomedicines  2022,10(1),195","journal-title":"Biomedicines"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","volume":"64","author":"Pirola C.J.","year":"2015","unstructured":"Pirola C.J.; Fern\u00e1ndez Gianotti T.; Casta\u00f1o G.O.; Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut  2015,64(5),800-812","journal-title":"Gut"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"e0142661","DOI":"10.1371\/journal.pone.0142661","volume":"10","author":"Becker P.P.","year":"2015","unstructured":"Becker P.P.; Rau M.; Schmitt J.; Performance of serum microRNAs -122, -192 and -21 as biomarkers in patients with non-alcoholic steatohepatitis. PLoS ONE  2015,10(11),e0142661","journal-title":"PLoS ONE"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/hep4.1445","volume":"4","author":"Akuta N.","year":"2020","unstructured":"Akuta N.; Kawamura Y.; Arase Y.; Circulating MicroRNA\u2010122 and fibrosis stage predict mortality of Japanese patients with histopathologically confirmed NAFLD. Hepatol Commun  2020,4(1),66-76","journal-title":"Hepatol Commun"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s43141-021-00257-5","volume":"19","author":"Mohamed A.A.","year":"2021","unstructured":"Mohamed A.A.; El-Demery A.; Al-Hussain E.; NAFLD mark: An accurate model based on microRNA-34 for diagnosis of non-alcoholic fatty liver disease patients. J Genet Eng Biotechnol  2021,19(1),157","journal-title":"J Genet Eng Biotechnol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/metabo12070588","volume":"12","author":"Malakootian M.","year":"2022","unstructured":"Malakootian M.; Naeli P.; Mowla S.J.; Seidah N.G.; Post-transcriptional effects of miRNAs on PCSK7 expression and function: miR-125a-5p, miR-143-3p, and miR-409-3p as negative regulators. Metabolites  2022,12(7),588","journal-title":"Metabolites"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"9298","DOI":"10.3390\/ijms23169298","volume":"23","author":"Quint\u00e1s G.","year":"2022","unstructured":"Quint\u00e1s G.; Caiment F.; Rienda I.; Quantitative prediction of steatosis in patients with non-alcoholic fatty liver by means of hepatic microRNAs present in serum and correlating with hepatic fat. Int J Mol Sci  2022,23(16),9298","journal-title":"Int J Mol Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11010-021-04269-0","volume":"477","author":"Hu M.J.","year":"2022","unstructured":"Hu M.J.; Long M.; Dai R.J.; Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p\/GRIA3. Mol Cell Biochem  2022,477(1),191-203","journal-title":"Mol Cell Biochem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10528-020-09971-0","volume":"58","author":"Wang D.R.","year":"2020","unstructured":"Wang D.R.; Wang B.; Yang M.; Suppression of miR-30a-3p attenuates hepatic steatosis in non-alcoholic fatty liver disease. Biochem Genet  2020,58(5),691-704","journal-title":"Biochem Genet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.3390\/ijms17101620","volume":"17","author":"Auguet T.","year":"2016","unstructured":"Auguet T.; Aragon\u00e8s G.; Berlanga A.; miR33a\/miR33b* and miR122 as possible contributors to hepatic lipid metabolism in obese women with nonalcoholic fatty liver disease. Int J Mol Sci  2016,17(10),1620","journal-title":"Int J Mol Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/jgh.12268","volume":"28","author":"Sharma H.","year":"2013","unstructured":"Sharma H.; Estep M.; Birerdinc A.; Expression of genes for micro RNA \u2010processing enzymes is altered in advanced non\u2010alcoholic fatty liver disease. J Gastroenterol Hepatol  2013,28(8),1410-1415","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.21037\/atm-22-6620","volume":"11","author":"Shen N.","year":"2023","unstructured":"Shen N.; Tang L.; Qian Y.; Serum miR-4488 as a potential biomarker of lean nonalcoholic fatty liver disease. Ann Transl Med  2023,11(4),173-3","journal-title":"Ann Transl Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.2147\/DMSO.S291595","volume":"14","author":"Hegazy M.A.","year":"2021","unstructured":"Hegazy M.A.; Abd ALgwad I, Abuel Fadl S, Sayed Hassan M, Ahmed Rashed L, Hussein MA. Serum Micro-RNA-122 level as a simple noninvasive marker of MAFLD severity. Diabetes Metab Syndr Obes  2021,14,2247-2254","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/1751-2980.12716","volume":"20","author":"He Z.","year":"2019","unstructured":"He Z.; Yang J.J.; Zhang R.; Circulating miR\u201029b positively correlates with non\u2010alcoholic fatty liver disease in a Chinese population. J Dig Dis  2019,20(4),189-195","journal-title":"J Dig Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12876-016-0557-6","volume":"16","author":"Akuta N.","year":"2016","unstructured":"Akuta N.; Kawamura Y.; Suzuki F.; Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterol  2016,16(1),141","journal-title":"BMC Gastroenterol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/liv.13097","volume":"36","author":"Braza-Bo\u00efls A.","year":"2016","unstructured":"Braza-Bo\u00efls A.; Mar\u00ed-Alexandre J.; Molina P.; Deregulated hepatic micro RNA s underlie the association between non\u2010alcoholic fatty liver disease and coronary artery disease. Liver Int  2016,36(8),1221-1229","journal-title":"Liver Int"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41371-021-00597-2","volume":"36","author":"Eikelis N.","year":"2022","unstructured":"Eikelis N.; Dixon J.B.; Lambert E.A.; MicroRNA-132 may be associated with blood pressure and liver steatosis\u2014preliminary observations in obese individuals. J Hum Hypertens  2022,36(10),911-916","journal-title":"J Hum Hypertens"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e0224820","DOI":"10.1371\/journal.pone.0224820","volume":"14","author":"Erhartova D.","year":"2019","unstructured":"Erhartova D.; Cahova M.; Dankova H.; Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation. PLoS One  2019,14(11),e0224820","journal-title":"PLoS One"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"9819","DOI":"10.1002\/jcp.29795","volume":"235","author":"Huang F.","year":"2020","unstructured":"Huang F.; Liu H.; Lei Z.; Long noncoding RNA CCAT1 inhibits miR\u2010613 to promote nonalcoholic fatty liver disease via increasing LXR\u03b1 transcription. J Cell Physiol  2020,235(12),9819-9833","journal-title":"J Cell Physiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"100409","DOI":"10.1016\/j.jhepr.2021.100409","volume":"4","author":"Johnson K.","year":"2022","unstructured":"Johnson K.; Leary P.J.; Govaere O.; Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Rep Innov Hepatol  2022,4(2),100409","journal-title":"JHEP Rep Innov Hepatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5604\/16652681.1193709","volume":"15","author":"Wang R.","year":"2016","unstructured":"Wang R.; Wang X.; Zhuang L.; Gene expression profiling reveals key genes and pathways related to the development of non-alcoholic fatty liver disease. Ann Hepatol  2016,15(2),190-199","journal-title":"Ann Hepatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cca.2013.05.021","volume":"424","author":"Yamada H.","year":"2013","unstructured":"Yamada H.; Suzuki K.; Ichino N.; Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta  2013,424,99-103","journal-title":"Clin Chim Acta"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41065-020-00136-y","volume":"157","author":"Zong Y.","year":"2020","unstructured":"Zong Y.; Yan J.; Jin L.; Relationship between circulating miR-132 and non-alcoholic fatty liver disease in a Chinese population. Hereditas  2020,157(1),22","journal-title":"Hereditas"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e0200847","DOI":"10.1371\/journal.pone.0200847","volume":"13","author":"Sendi H.","year":"2018","unstructured":"Sendi H.; Mead I.; Wan M.; miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. PLoS One  2018,13(7),e0200847","journal-title":"PLoS One"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.3892\/etm.2021.10865","volume":"22","author":"Hu L.K.","year":"2021","unstructured":"Hu L.K.; Chen J.Q.; Zheng H.; Tao Y.P.; Yang Y.; Xu X.F.; MicroRNA-506-3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis. Exp Ther Med  2021,22(6),1430","journal-title":"Exp Ther Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2036.2010.04366.x","volume":"32","author":"Estep M.","year":"2010","unstructured":"Estep M.; Armistead D.; Hossain N.; Differential expression of miRNAs in the visceral adipose tissue of patients with non\u2010alcoholic fatty liver disease. Aliment Pharmacol Ther  2010,32(3),487-497","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"3960197","DOI":"10.1155\/2017\/3960197","volume":"2017","author":"Guo X.Y.","year":"2017","unstructured":"Guo X.Y.; Chen J.N.; Sun F.; Wang Y.Q.; Pan Q.; Fan J.G.; circRNA_0046367 prevents hepatoxicity of lipid peroxidation: An inhibitory role against hepatic steatosis. Oxid Med Cell Longev  2017,2017(1),3960197","journal-title":"Oxid Med Cell Longev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","volume":"79","author":"Harrison S.A.","year":"2023","unstructured":"Harrison S.A.; Ratziu V.; Magnanensi J.; NIS2+\u2122, an optimisation of the blood-based biomarker NIS4\u00ae technology for the detection of at-risk NASH: A prospective derivation and validation study. J Hepatol  2023,79(3),758-767","journal-title":"J Hepatol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"614","DOI":"10.52547\/rbmb.11.4.614","volume":"11","author":"Abdelgwad M.","year":"2023","unstructured":"Abdelgwad M.; Zakaria R.; Marzouk S.; The emerging role of circular RNA homeodomain interacting protein kinase 3 and circular RNA 0046367 through Wnt\/beta-catenin pathway on the pathogenesis of nonalcoholic steatohepatitis in Egyptian patients. Rep Biochem Mol Biol  2023,11(4),614-625","journal-title":"Rep Biochem Mol Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"11740","DOI":"10.1080\/21655979.2022.2072602","volume":"13","author":"Chen S.","year":"2022","unstructured":"Chen S.; Cai X.; Liu Y.; The macrophage-associated microRNA-4715-3p\/Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: Evidence from transcriptome and biological data. Bioengineered  2022,13(5),11740-11751","journal-title":"Bioengineered"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"154789","DOI":"10.1016\/j.cyto.2019.154789","volume":"123","author":"Hanson A.","year":"2019","unstructured":"Hanson A.; Piras I.S.; Wilhelmsen D.; Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p. Cytokine  2019,123,154789","journal-title":"Cytokine"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jhep.2014.10.004","volume":"62","author":"Bandiera S.","year":"2015","unstructured":"Bandiera S.; Pfeffer S.; Baumert T.F.; Zeisel M.B.; miR-122 \u2013 A key factor and therapeutic target in liver disease. J Hepatol  2015,62(2),448-457","journal-title":"J Hepatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s43141-023-00467-z","volume":"21","author":"Ragab H.M.","year":"2023","unstructured":"Ragab H.M.; Ezzat W.M.; Hassan E.M.; Significance of MiRNA-34a and MiRNA-192 as a risk factor for nonalcoholic fatty liver disease. J Genet Eng Biotechnol  2023,21(1),13","journal-title":"J Genet Eng Biotechnol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8635329","volume":"2018","author":"Li C.W.","year":"2018","unstructured":"Li C.W.; Chiu Y.K.; Chen B.S.; Investigating pathogenic and hepatocarcinogenic mechanisms from normal liver to HCC by constructing genetic and epigenetic networks via big genetic and epigenetic data mining and genome-wide NGS data identification. Dis Markers  2018,2018,1-22","journal-title":"Dis Markers"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.3390\/cells11213517","volume":"11","author":"Wang D.","year":"2022","unstructured":"Wang D.; Hu X.; Chen J.; Bioinformatics analysis and validation of the role of Lnc-RAB11B-AS1 in the development and prognosis of hepatocellular carcinoma. Cells  2022,11(21),3517","journal-title":"Cells"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.trsl.2015.04.014","volume":"166","author":"Leti F.","year":"2015","unstructured":"Leti F.; Malenica I.; Doshi M.; High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease\u2013related fibrosis. Transl Res  2015,166(3),304-314","journal-title":"Transl Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e0220406","DOI":"10.1371\/journal.pone.0220406","volume":"14","author":"Vogt J.","year":"2019","unstructured":"Vogt J.; Sheinson D.; Katavolos P.; Variance component analysis of circulating miR-122 in serum from healthy human volunteers. PLoS One  2019,14(7),e0220406","journal-title":"PLoS One"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ncrna.2023.06.004","volume":"8","author":"Aghajanzadeh T.","year":"2023","unstructured":"Aghajanzadeh T.; Talkhabi M.; Zali M.R.; Hatami B.; Baghaei K.; Diagnostic potential and pathogenic performance of circulating miR-146b, miR-194, and miR-214 in liver fibrosis. Noncoding RNA Res  2023,8(4),471-480","journal-title":"Noncoding RNA Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/13813455.2022.2046106","volume":"130","author":"BinMowyna MN","year":"2024","unstructured":"BinMowyna MN; AlFaris NA; Al-Sanea EA; AlTamimi JZ; Aldayel TS; Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a\/SIRT1 axis. Arch Physiol Biochem  2024,130(3),300-315","journal-title":"Arch Physiol Biochem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"119030","DOI":"10.1016\/j.jep.2024.119030","volume":"338","author":"Liang M.","year":"2025","unstructured":"Liang M.; Xiao X.; Chen M.; Artemisia capillaris Thunb. Water extract alleviates metabolic dysfunction-associated Steatotic liver disease Disease by inhibiting miR-34a-5p to activate Sirt1-mediated hepatic lipid metabolism. J Ethnopharmacol  2025,338(Pt 2),119030","journal-title":"J Ethnopharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/13813455.2019.1640744","volume":"127","author":"Hu Y.","year":"2021","unstructured":"Hu Y.; Du G.; Li G.; Peng X.; Zhang Z.; Zhai Y.; The miR-122 inhibition alleviates lipid accumulation and inflammation in NAFLD cell model. Arch Physiol Biochem  2021,127(5),385-389","journal-title":"Arch Physiol Biochem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/genes12111813","volume":"12","author":"Albadawy R.","year":"2021","unstructured":"Albadawy R.; Agwa S.H.A.; Khairy E.; Circulatory Endothelin 1-Regulating RNAs panel: Promising biomarkers for non-invasive NAFLD\/NASH diagnosis and stratification: clinical and molecular pilot study. Genes (Basel)  2021,12(11),1813","journal-title":"Genes (Basel)"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"356","DOI":"10.15403\/jgld-5065","volume":"32","author":"Rusu I.","year":"2023","unstructured":"Rusu I.; Pirlog R.; Chiroi P.; Distinct morphological and molecular profiles of NAFLD and NAFLD-associated HCC revealed by immunohistochemistry and microRNA analysis. J Gastrointestin Liver Dis  2023,32(3),356-366","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref=49","first-page":"377","volume":"42","author":"Muhammad Yusuf A.N.","year":"2020","unstructured":"Muhammad Yusuf A.N.; Raja Ali R.A.; Muhammad Nawawi K.N.; Mokhtar N.M.; Potential biomarkers in NASH-induced liver cirrhosis with hepatocellular carcinoma: A preliminary work on roles of exosomal miR-182, miR-301a, and miR-373. Malays J Pathol  2020,42(3),377-384","journal-title":"Malays J Pathol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"100756","DOI":"10.1016\/j.aohep.2022.100756","volume":"27","author":"L\u00f3pez-S\u00e1nchez G.N.","year":"2022","unstructured":"L\u00f3pez-S\u00e1nchez G.N.; Montalvo-Jav\u00e9 E.; Dom\u00ednguez-Perez M.; Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD. Ann Hepatol  2022,27(6),100756","journal-title":"Ann Hepatol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1136\/gutjnl-2015-309456","volume":"65","author":"Zarrinpar A.","year":"2016","unstructured":"Zarrinpar A.; Gupta S.; Maurya M.R.; Subramaniam S.; Loomba R.; Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: A prospective study. Gut  2016,65(9),1546-1554","journal-title":"Gut"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.3390\/ijms24043875","volume":"24","author":"Mollet I.G.","year":"2023","unstructured":"Mollet I.G.; Macedo M.P.; Pre-diabetes-linked miRNA miR-193b-3p targets PPARGC1A, disrupts metabolic gene expression profile and increases lipid accumulation in hepatocytes: Relevance for MAFLD. Int J Mol Sci  2023,24(4),3875","journal-title":"Int J Mol Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3390\/cells9081767","volume":"9","author":"Markovic J.","year":"2020","unstructured":"Markovic J.; Sharma A.D.; Balakrishnan A.; MicroRNA-221: A fine tuner and potential biomarker of chronic liver injury. Cells  2020,9(8),1767","journal-title":"Cells"}],"container-title":["MicroRNA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0122115366359521250122115511","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/239208\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0122115366359521250122115511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T04:38:49Z","timestamp":1765427929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/239208\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0122115366359521250122115511","relation":{},"ISSN":["2211-5366"],"issn-type":[{"value":"2211-5366","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-10-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}